Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Browse By Topic
Immunotherapy
Immunotherapy
Checkpoint Inhibitors Show Promise in Patients with Mesothelioma
By
Phoebe Starr
Immunotherapy
,
Personalized Medicine
,
Mesothelioma
August 2017, Vol 8, No 4 | Payers' Perspectives In Oncology: ASCO 2017 Highlights
Chicago, IL—Immunotherapy holds promise as second-line or third-line treatment of patients with malignant pleural mesothelioma, a rare cancer with increasing incidence. Early findings from the ongoing, phase 2 MAPS-2 clinical trial showed that immunotherapy slowed the growth of malignant pleural mesothelioma after relapse, reported lead investigator Arnaud Scherpereel, MD, PhD, Head, Pulmonary and Thoracic Oncology Department, University Hospital of Lille, France, at the 2017 ASCO annual meeting. MAPS-2 is the largest clinical trial to date of immune checkpoint inhibitor therapy in patients with malignant pleural mesothelioma.
Read Article
Pembrolizumab Makes Inroads in Sarcoma Subtypes
By
Phoebe Starr
Immunotherapy
,
Personalized Medicine
August 2017, Vol 8, No 4 | Payers' Perspectives In Oncology: ASCO 2017 Highlights
Chicago, IL—The tumor types amenable to immunotherapy with the PD-1 inhibitor pembrolizumab (Keytruda) keep expanding and now include sarcoma, which has been difficult to treat.
Read Article
Adoptive T-Cell Therapy: Ready for Prime Time
By
Chase Doyle
Immunotherapy
,
Personalized Medicine
August 2017, Vol 8, No 4 | Payers' Perspectives In Oncology: ASCO 2017 Highlights
Chicago, IL—Chimeric antigen receptor (CAR) T-cell therapy is changing cancer care. In 2010, there were just 3 CAR T-cell clinical trials. As of May 2017, 183 clinical trials are underway, and for the first time, there are more clinical trials in China than in the United States, according to Carl H. June, MD, Director, Translational Research Program, University of Pennsylvania, Philadelphia, at the 2017 ASCO annual meeting. Dr June discussed how this rapidly evolving technology is taking immuno-oncology to the “next level” of precision medicine.
Read Article
Longest Follow-Up in Patients with NSCLC Who Responded to Immunotherapy with Nivolumab
By
Phoebe Starr
Immunotherapy
,
Personalized Medicine
June 2017, Vol 8, No 3
Washington, DC—In the longest follow-up on single-agent nivolumab (Opdivo) to date, 5-year overall survival was 16% in patients with advanced non–small-cell lung cancer (NSCLC) in the updated results of a phase 1b dose-ranging study (CA209-003). This represents a quadrupling of 5-year overall survival with standard platinum doublets, which is approximately 4% for patients with metastatic NSCLC.
Read Article
Immunotherapy-Related Adverse Reactions: Grading of Symptoms Key to Appropriate Management
By
Wayne Kuznar
Immunotherapy
,
Personalized Medicine
June 2017, Vol 8, No 3
Orlando, FL—Enthusiasm for immunotherapy in the treatment of cancer must be balanced with a healthy respect for the power of T-cell activation. Autoimmunity is recognized as an effect of prolonged T-cell activation via PD-1/PD ligand 1 inhibition. Although immune-related adverse events are generally easily managed, they occasionally can be fatal and therefore should be managed without delay, said Stephanie Andrews, MS, ANP-BC, a hospitalist specializing in medical oncology at Moffitt Cancer Center, Tampa, FL, at the 2017 National Comprehensive Cancer Network (NCCN) annual conference.
Read Article
Immune Stimulant Fails Randomized Test in Platinum-Resistant Ovarian Cancer
By
Charles Bankhead
Immunotherapy
,
Personalized Medicine
June 2017, Vol 8, No 3
National Harbor, MD—Platinum-resistant ovarian cancer also appeared resistant to the immunotherapeutic effects of the toll-like receptor 8 (TLR8) agonist motolimod as add-on to chemotherapy, according to results of a randomized trial.
Read Article
Adding Indoximod to Pembrolizumab Boosts Immune Response in Melanoma
By
Phoebe Starr
Immunotherapy
,
Personalized Medicine
June 2017, Vol 8, No 3
Washington, DC—Adding the investigational drug indoximod, an indoleamine 2,3-dioxygenase (IDO) pathway inhibitor, to the checkpoint inhibitor pembrolizumab (Keytruda) led to higher response rates in patients with advanced melanoma than what is reported with pembrolizumab monotherapy, said lead investigator Yousef Zakharia, MD, Clinical Assistant Professor of Internal Medicine, Division of Hematology, Oncology and Blood and Marrow Transplantation, University of Iowa, Iowa City, at the 2017 American Association for Cancer Research meeting.
Read Article
Atezolizumab plus Bevacizumab Combo Shows Promise in Patients with Metastatic Kidney Cancer
By
Phoebe Starr
Immunotherapy
,
Personalized Medicine
June 2017, Vol 8, No 3
Orlando, FL—Atezolizumab plus bevacizumab showed encouraging responses as a first-line treatment of metastatic renal-cell carcinoma in a phase 2 trial. Although the trial failed to meet its primary end point of significant improvement in progression-free survival (PFS) compared with sunitinib, the combination did reduce the risk for death or disease progression by 36% in patients with elevated PD ligand 1 (PD-L1) expression. The median PFS was almost double in the PD-L1–positive group with atezolizumab plus bevacizumab versus sunitinib (14.7 months vs 7.8 months, respectively).
Read Article
NCCN Lung Cancer Guidelines: Combinations May Be the Future of Immunotherapy
By
Wayne Kuznar
Immunotherapy
,
NCCN Conference Highlights
,
Personalized Medicine
June 2017, Vol 8, No 3
Orlando, FL—Immunotherapy is now an established option for patients with non–small-cell lung cancer (NSCLC) in the second-line setting and in selected patients in the first-line setting.
Read Article
Immunotherapy with Nivolumab plus Ipilimumab Improves Outcomes in Metastatic Urothelial Cancer
By
Walter Alexander
Immunotherapy
,
Personalized Medicine
April 2017, Vol 8, No 2
National Harbor, MD—Results of a phase 1/2 study that investigated 2 dosing regimens of 2 immunotherapies—the PD-1 inhibitor nivolumab (Opdivo) plus the CTLA-4 inhibitor ipilimumab (Yervoy)—in patients with previously treated metastatic urothelial carcinoma showed higher response rates and longer median overall survival with the regimen of nivolumab 1 mg/kg plus ipilimumab 3 mg/kg than with the dosing of nivolumab 3 mg/kg plus ipilimumab 1 mg/kg.
Read Article
Page 4 of 5
1
2
3
4
5
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma